Immunome Inc. (IMNM) financials: revenue, earnings and cash flow
Fiscal 2019–2025 · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$212M, a net margin of -3060.0%; the best year in this period was 2019 with -$10M.
Free cash flow was -$201M in fiscal 2025 and positive in 0 of the 7 years shown.
The diluted share count rose 7885% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7M | $9M | $14M | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | -$224M | -$306M | -$110M | -$37M | -$25M | -$12M | -$10M |
| Net income | -$212M | -$293M | -$107M | -$37M | -$25M | -$18M | -$10M |
| EPS (diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-5.26 | $-9.55 |
| R&D | $177M | $130M | $23M | $23M | $14M | $7M | $9M |
| Revenue growth | −23.2% | −35.5% | — | — | — | — | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$191M | -$111M | -$8M | -$29M | -$18M | -$12M | -$10M |
| Capital spending | -$10M | -$7M | -$831000 | -$248000 | -$79000 | -$586000 | -$233000 |
| Free cash flow | -$201M | -$118M | -$8M | -$29M | -$18M | -$13M | -$10M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | $26M | $16M | $6M | $5M | $3M | $621000 | $14000 |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Cash | $653M | $217M | $138M | $20M | $49M | $40M | $3M |
| Debt | $4M | $5M | $2M | — | $500000 | $500000 | — |
| Equity | $634M | $181M | $120M | $17M | $48M | $41M | -$36M |
| Total assets | $683M | $240M | $149M | $24M | $58M | $45M | $5M |
| Shares (diluted) | 87M | 59M | 20M | 12M | 12M | 3M | 1M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | -3228.8% | -3382.4% | -781.4% | — | — | — | — |
| Net margin | -3060.0% | -3240.4% | -761.9% | — | — | — | — |
| FCF margin | -2890.1% | -1304.8% | -59.9% | — | — | — | — |
| ROIC | -27.7% | -129.9% | -71.2% | -175.0% | -40.9% | -23.2% | — |
| ROE | -33.5% | -161.7% | -89.1% | -221.6% | -51.3% | -43.1% | 29.3% |
Frequently asked questions
What is Immunome’s annual revenue?
$7M in fiscal 2025.
How much profit does Immunome make?
Net income was -$212M in fiscal 2025 (net margin -3060.0%).
Is Immunome’s revenue growing?
No: revenue fell 23.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.